Cidara Therapeutics, Inc. (NASDAQ:CDTX - Get Free Report) COO Shane Ward sold 1,664 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $21.96, for a total value of $36,541.44. Following the transaction, the chief operating officer now directly owns 14,674 shares in the company, valued at approximately $322,241.04. This trade represents a 10.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Cidara Therapeutics Stock Performance
Shares of Cidara Therapeutics stock opened at $22.36 on Friday. Cidara Therapeutics, Inc. has a 52-week low of $10.00 and a 52-week high of $28.42. The stock has a market cap of $157.57 million, a PE ratio of -0.88 and a beta of 0.88. The firm has a 50-day moving average of $22.27 and a 200-day moving average of $17.67.
Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($5.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.28) by ($0.10). Cidara Therapeutics had a negative net margin of 289.05% and a negative return on equity of 69.64%. Equities research analysts predict that Cidara Therapeutics, Inc. will post -8.74 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research analysts have recently commented on the company. Citizens Jmp initiated coverage on Cidara Therapeutics in a research note on Wednesday. They set an "outperform" rating and a $46.00 target price for the company. Royal Bank of Canada started coverage on shares of Cidara Therapeutics in a research report on Friday, December 13th. They set an "outperform" rating and a $34.00 price objective for the company. Citigroup assumed coverage on shares of Cidara Therapeutics in a research report on Wednesday. They issued an "outperform" rating on the stock. HC Wainwright raised their target price on shares of Cidara Therapeutics from $24.00 to $35.00 and gave the stock a "buy" rating in a research note on Monday. Finally, JMP Securities set a $46.00 price target on shares of Cidara Therapeutics in a research note on Wednesday. One analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Cidara Therapeutics has an average rating of "Buy" and an average price target of $39.14.
View Our Latest Stock Report on CDTX
Institutional Investors Weigh In On Cidara Therapeutics
Several institutional investors have recently made changes to their positions in CDTX. Point72 Asia Singapore Pte. Ltd. acquired a new position in Cidara Therapeutics in the 4th quarter valued at $56,000. Northern Trust Corp increased its position in shares of Cidara Therapeutics by 6.8% in the fourth quarter. Northern Trust Corp now owns 33,957 shares of the biotechnology company's stock worth $913,000 after purchasing an additional 2,170 shares during the period. Point72 Asset Management L.P. acquired a new position in Cidara Therapeutics in the fourth quarter valued at about $165,000. Geode Capital Management LLC raised its stake in Cidara Therapeutics by 22.7% in the third quarter. Geode Capital Management LLC now owns 52,898 shares of the biotechnology company's stock valued at $569,000 after purchasing an additional 9,771 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp bought a new stake in Cidara Therapeutics during the fourth quarter worth about $339,000. 35.82% of the stock is currently owned by institutional investors.
About Cidara Therapeutics
(
Get Free Report)
Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
